Fibrosis

Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community

Retrieved on: 
Thursday, March 7, 2024
Central nervous system, Biotechnology, Medicine, Research, Inflammation, Medical imaging, Biomarker, CNS, Patient, Fibrosis, Gastroenterology, Software, Radiation

This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.

Key Points: 
  • This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.
  • The enlarged Group ("Group") formed through this strategic combination will see 100% of Invicro being acquired by Calyx from its current owner, REALM IDx, Inc.
  • The transaction is subject to regulatory filings and customary closing conditions and is expected to complete in Q2 2024.
  • Calyx and Invicro each provide complementary services to most of the world's leading pharma and biotechnology companies.

Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community

Retrieved on: 
Thursday, March 7, 2024
Central nervous system, Biotechnology, Medicine, Research, Inflammation, Medical imaging, Biomarker, CNS, Patient, Fibrosis, Gastroenterology, Software, Radiation

This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.

Key Points: 
  • This complementary combination will create a new global leader in the provision of medical imaging solutions and development services to the clinical research community.
  • The transaction is subject to regulatory filings and customary closing conditions and is expected to complete in Q2 2024.
  • Calyx and Invicro each provide complementary services to most of the world's leading pharma and biotechnology companies.
  • This exciting union will create a truly differentiated industry leader and provides a clear response to growing customer requirements for broader support.

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
Tuesday, March 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis (PSC)

Retrieved on: 
Thursday, February 29, 2024
PSC, Inflammation, AASLD, FDA, Physician, Food, Drug development, Part, Primary sclerosing cholangitis, Ascending cholangitis, ODD, Safety, Attention, Hepatology, Biomarker, Inflammatory bowel disease, Patient, Fibrosis, Clinical trial, IBD, IND, LBP, Pharmaceutical industry

LISCure anticipates treating the first patient in the upcoming months and expects topline results for Part 1 in the first half of 2025.

Key Points: 
  • LISCure anticipates treating the first patient in the upcoming months and expects topline results for Part 1 in the first half of 2025.
  • PSC is a rare, chronic, cholestatic liver disease with very high unmet medical needs where there are no approved drugs.
  • LISCure confirmed the safety, tolerability, and key biomarkers of LB-P8 in a Phase 1 study and received Orphan Drug Designation (ODD) for the treatment of PSC from the U.S. FDA.
  • LB-P8 was presented in oral presentations at the American Association for the Study of Liver Diseases (AASLD) every year for the past two years.

Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award

Retrieved on: 
Wednesday, February 28, 2024
LRA, Engineering, Chronic kidney disease, LMTA, Immune system, Infection, Thrombus, Inflammation, Physician, Kidney disease, Quality of life, Lupus Research Alliance, Colchicine, Lupus, Nephritis, NETS, CD19, Skin, Cell, UV, Risk, Autoantibody, APS, Bacteria, Death, Agent handling, Mortal Kombat, Fibrosis, Clinical trial, Gene, Survival, Disease, Antiphospholipid syndrome, Kidney, SLE, S100A4, Research, DNA, Kidney failure, Vaccine

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).
  • The development of targeted treatments is hindered by an incomplete understanding of lupus and its devastating complications.
  • These seven talented investigators will identify targets for new treatments and test novel therapeutic avenues to revolutionize the field and improve the lives of individuals with lupus.
  • Surgical biopsies of the kidneys are often needed to diagnose lupus nephritis (LN), kidney inflammation caused by lupus that can result in severe and sometimes life-threatening organ damage.

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Retrieved on: 
Tuesday, February 20, 2024
Bangladesh Technical Education Board, Research, Fibrosis, Molecule, ARS, NIH, Inflammation, IL-6, FDA, TEL, Food, Acute radiation syndrome, RNCP, Radiation, Mustard gas, COVID-19, Canadian International Council, Survival, Opaganib, Medical imaging

The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.

Key Points: 
  • The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy.
  • Radiation-induced inflammation is known to occur in two phases – in an initial inflammatory response immediately after irradiation and in a delayed response that can occur weeks later.
  • Thus, treating with opaganib during both initial and delayed phases of inflammation provided the greatest improvement in survival.
  • "These data further demonstrate that sphingolipid metabolism is a critical regulator of fibrogenesis, and specifically show that opaganib suppresses radiation-induced pulmonary inflammation and fibrosis."

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Retrieved on: 
Tuesday, February 20, 2024
Patent office, Fast Track, Therapy, Fibrosis, Doctor of Philosophy, Orphan drug, PSC, Inflammation, TEL, FDA, Patent, Treatment, Use, Primary sclerosing cholangitis, Composition, Liver transplantation, CMMB, Chemokine, Liver, CCL24, Antibody, Pharmaceutical industry

TEL AVIV, Israel, Feb. 20, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • In clinical and preclinical studies, this distinctive approach has been shown to inhibit fibrogenesis and interfere with core PSC pathways.
  • and the FDA recently awarded CM-101 Fast Track designation for the treatment of PSC in adults.

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Retrieved on: 
Thursday, February 15, 2024
IPF, University of Alabama, ALRN, CAV-1, Idiopathic pulmonary fibrosis, ID, Weill Cornell Medicine, Doctor of Philosophy, University, Therapy, Webcast, Patient, Fibrosis, Disease, University of Giessen, Pharmaceutical industry

ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S.

Key Points: 
  • ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S.
  • “As practicing clinicians and experts in pulmonary care medicine, these key opinion leaders bring valuable experience to the discussion of LTI-03 as a potential treatment option for patients with IPF,” said Cory Hogaboam, Ph.D., Chief Scientist of Aileron.
  • Studies conducted by Aileron and third parties have demonstrated that Cav1 is a key protein in the regulation of lung fibrosis that has a decreased expression in IPF patients.
  • A replay of the webcast will be available following the completion of the event.

GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024

Retrieved on: 
Wednesday, February 14, 2024
Enzyme replacement therapy, Fabry disease, ICV, EMA, Intelligence, European, Glycolipid, ERT, Sanfilippo syndrome, Hunter syndrome, Death, MPS, Prevalence, ODD, Safety, Sanfilippo, IDS, Disorder, Patient, Hanmi Pharmaceutical, Fibrosis, Clinical trial, Knowledge, Kidney disease, Disease, Urine, Heart, Alpha-galactosidase, Phase, Male, Kidney, Glycogen storage disease, Brain, Orphan, Mouse, Pharmaceutical industry

YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.

Key Points: 
  • YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.
  • WorldSymposium 2024 is an international forum for Lysosomal Diseases experts to share and exchange insights for researching better treatment of the disease.
  • In 2012, GC Biopharma succeeded in developing the world's second treatment for Hunter syndrome, "Hunterase" solely using domestic technology.
  • GC Biopharma, together with Hanmi Pharmaceutical, is developing GC1134A/HM15421, a long-acting alpha-galactosidase that can be administered subcutaneously once a month to improve patient convenience.

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Retrieved on: 
Thursday, February 8, 2024
Principal, ALT, Liver failure, Fatty liver disease, Cirrhosis, Hepatotoxicity, Nausea, GGT, Death, Therapy, Biomarker, Patient, Breakthrough therapy, Safety, Incidence, FDA, NAFLD, Lipoprotein, Priority review, Diarrhea, NAS, Woman, University of Oxford, Disease, Drug development, Fibrosis, Biopsy, Risk, Week, Heart rate, PDUFA, CAP, NASH, Medicine, Liver cancer, Liver, Pharmaceutical industry

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom received Breakthrough Therapy designation from the FDA and is under review to become the first medicine approved to treat patients with NASH with liver fibrosis.
  • Approximately 50% of patients treated with resmetirom 100 mg with biopsies at Week 52 showed either NASH resolution or fibrosis improvement.
  • More than 80% of patients with biopsies at Week 52 had either fibrosis reversal or no progression of fibrosis.